Clonal haematopoiesis is associated with higher mortality in patients with cardiogenic shock

Scolari F. L., Abelson S., Brahmbhatt D. H., Medeiros J. J., Fan C. S., Fung N. L., ...More

European Journal of Heart Failure, vol.24, no.9, pp.1573-1582, 2022 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 24 Issue: 9
  • Publication Date: 2022
  • Doi Number: 10.1002/ejhf.2588
  • Journal Name: European Journal of Heart Failure
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CINAHL, EMBASE, MEDLINE
  • Page Numbers: pp.1573-1582
  • Keywords: Cardiogenic shock, Heart failure, Clonal haematopoiesis, Inflammation, Somatic mutations, Cytokines
  • TED University Affiliated: No


© 2022 European Society of Cardiology.Aims: Cardiogenic shock (CS) with variable systemic inflammation may be responsible for patient heterogeneity and the exceedingly high mortality rate. Cardiovascular events have been associated with clonal haematopoiesis (CH) where specific gene mutations in haematopoietic stem cells lead to clonal expansion and the development of inflammation. This study aims to assess the prevalence of CH and its association with survival in a population of CS patients in a quaternary centre. Methods and results: We compared the frequency of CH mutations among 341 CS patients and 345 ambulatory heart failure (HF) patients matched for age, sex, ejection fraction, and HF aetiology. The association of CH with survival and levels of circulating inflammatory cytokines was analysed. We detected 266 CH mutations in 149 of 686 (22%) patients. CS patients had a higher prevalence of CH-related mutations than HF patients (odds ratio 1.5; 95% confidence interval [CI] 1.0–2.1, p = 0.02) and was associated with decreased survival (30 days: hazard ratio [HR] 2.7; 95% CI 1.3–5.7, p = 0.006; 90 days: HR 2.2; 95% CI 1.3–3.9, p = 0.003; and 3 years: HR 1.7; 95% CI 1.1–2.8, p = 0.01). TET2 or ASXL1 mutations were associated with lower survival in CS patients at all time-points (p ≤ 0.03). CS patients with TET2 mutations had higher circulating levels of SCD40L, interferon-γ, interleukin-4, and tumour necrosis factor-α (p ≤ 0.04), while those with ASXL1 mutations had decreased levels of CCL7 (p = 0.03). Conclusions: Cardiogenic shock patients have high frequency of CH, notably mutations in TET2 and ASXL1. This was associated with reduced survival and dysregulation of circulating inflammatory cytokines in those CS patients with CH.